Global Market Study on Osteoporosis Drugs: North America to Remain Demand Hub through 2031

Jul 2021| PMR1689A| Persistence Market Research

Report Highlights

Osteoporosis Drugs Market: Report Scope

Osteoporosis is a progressive, skeletal disease, leading to fragile and abnormally porous bones. It is characterized by decrease in bone density, strength, and micro-architectural deterioration of bone tissue resulting in thinning or weakening of bones with an increased propensity of fractures.

Primary and secondary osteoporosis are the major types of osteoporosis. Some of the factors leading to osteoporosis are genetic factor, aging, lack of calcium and vitamin D, smoking, lack of exercise, low body weight, excessive alcohol consumption, history of rheumatoid arthritis, menopause, and certain medication.

Osteoporosis can be diagnosed using X-ray and can be confirmed by bone density scan. Dual energy X-ray absorptiometry (DEXA) is the common bone density test used to measure the density of bones. Treatment for osteoporosis begins with a change in lifestyle and diet. It can be prevented and treated with the help of calcium and vitamin D supplements, exercise, and osteoporosis medications. Prevalence of osteoporosis is high among people aged 60 years and above.

Moreover, estrogen plays a vital role in regulating the bone growth process in women. Post menopause, bone breakdown outpaces the building of new bone matter. The rate of bone loss in women increases after menopause, leading to the threat of developing osteoporosis.

North America is the largest market for osteoporosis drugs due to increasing geriatric population, growing investment in R&D for the discovery of innovative drugs, and rising prevalence of lifestyle-associated diseases in the region. Asia-Pacific is expected to exhibit high growth rates over the following five years in the global osteoporosis drugs market.

China and India are expected to be the fastest-growing markets for osteoporosis drugs in Asia Pacific. Some of the key driving forces for the osteoporosis drugs market in emerging countries are rising geriatric population, a large pool of patients, changing lifestyles, increasing healthcare expenditure, and growing awareness about osteoporosis care in these regions.

Rising geriatric population, changing lifestyle impinging bone health, and increasing prevalence of osteoporosis in post-menopausal women are some of the factors driving the growth of the global osteoporosis drugs market. In addition, increasing awareness about osteoporosis care and growing investments in R&D for the discovery of innovative drugs are also fueling the growth of the market.

On the other hand, side effects and complications such as irritable bowel syndrome, nausea, and ulcers in stomach or esophagus, associated with osteoporosis drugs and patent expiration of osteoporosis drugs are inhibiting growth of the global osteoporosis drugs market.

Key Features of Report

  • Drivers, restraints, and challenges shaping the osteoporosis drugs market dynamics
  • Latest innovations and key events in the market
  • Analysis of business strategies of the top players in the market
  • Osteoporosis drugs market estimates and forecasts
  • Table 1 : Market snapshot: osteoporosis drugs market, 2021and 2031 10
  • Table 2 : Drivers for osteoporosis drugs market: Impact analysis 20
  • Table 3 : Patent expiration of various osteoporosis drugs 22
  • Table 4 : Restraints for global osteoporosis drugs market: Impact analysis 23
  • Table 5 : Global osteoporosis drugs market size, by region, 2016 – 2020 (US$ Mn) 24
  • Table 6 : Global osteoporosis drugs market size, by region, 2021 – 2031 (US$ Mn) 25
  • Table 7 : Global osteoporosis drugs market size, by type, 2016 – 2020 (US$ Mn) 26
  • Table 8 : Global osteoporosis drugs market size, by type, 2021 – 2031 (US$ Mn) 27
  • Table 9 : Risk reduction of fracture with bisphosphonates over 3–4 years 28
  • Table 10 : Global bisphosphonates drugs market size, by region, 2016 – 2020 (US$ Mn) 29
  • Table 11 : Global bisphosphonates drugs market size, by region, 2021 – 2031 (US$ Mn) 30
  • Table 12 : Global parathyroid hormone therapy drugs market size, by region, 2016 – 2020 (US$ Mn) 31
  • Table 13 : Global parathyroid hormone therapy drugs market size, by region, 2021 – 2031 (US$ Mn) 32
  • Table 14 : Global calcitonin drugs market size, by region, 2016 – 2020 (US$ Mn) 33
  • Table 15 : Global calcitonin drugs market size, by region, 2021 – 2031 (US$ Mn) 34
  • Table 16 : Global SERMs drugs market size, by region, 2016 – 2020 (US$ Mn) 35
  • Table 17 : Global SERMs drugs market size, by region, 2021 – 2031 (US$ Mn) 36
  • Table 18 : Global RANK ligand inhibitors drugs market size, by region, 2016 – 2020 (US$ Mn) 37
  • Table 19 : Global RANK ligand inhibitors drugs market size, by region, 2021 – 2031 (US$ Mn) 38
  • Table 20 : North America osteoporosis drugs market size, by country, 2016 – 2020 (US$ Mn) 40
  • Table 21 : North America osteoporosis drugs market size, by country, 2021 – 2031 (US$ Mn) 41
  • Table 22 : Europe osteoporosis drugs market size, by country, 2016 – 2020 (US$ Mn) 43
  • Table 23 : Europe osteoporosis drugs market size, by country, 2021 – 2031 (US$ Mn) 44
  • Table 24 : Asia Pacific osteoporosis drugs market size, by country, 2016 – 2020 (US$ Mn) 46
  • Table 25 : Asia Pacific osteoporosis drugs market size, by country, 2021 – 2031 (US$ Mn) 47
  • Table 26 : Major products of Eli Lilly and Company 50
  • Table 27 : Major products of F. Hoffmann-La Roche, Ltd. 52
  • Table 28 : Major products of Merck & Co., Inc. 54
  • Table 29 : Major products of Novartis AG 56
  • Table 30 : Major products of Amgen, Inc. 58
  • Table 31 : Major products of Novo Nordisk A/S 60
  • Table 32 : Major products of Actavis plc 62
  • Table 33 : Major products of Pfizer, Inc. 65
  • Table 34 : Major products of GlaxoSmithKline plc 67
  • Table 35 : Major products of Teva Pharmaceutical Industries Ltd. 69
  • Figure 1 : Osteoporosis drugs market Porter’s five force analysis 11
  • Figure 2 : Risk factors for osteoporosis 14
  • Figure 3 : Prevention of osteoporosis 15
  • Figure 4 : Aging population in major regions, 2000 – 2050 (% share in total population) 17
  • Figure 5 : Decrease of bone mass with onset of menopause 19
  • Figure 6 : Global osteoporosis drugs market share, by region, by value, 2021 24
  • Figure 7 : Global osteoporosis drugs market share, by type, by value, 2021 26
  • Figure 8 : Global bisphosphonates drugs market share, by region, by value, 2021 29
  • Figure 9 : Global parathyroid hormone therapy drugs market share, by region, by value, 2021 31
  • Figure 10 : Global calcitonin drugs market share, by region, by value, 2021 33
  • Figure 11 : Global SERMs drugs market share, by region, by value, 2021 35
  • Figure 12 : Global RANK ligand inhibitors drug market share, by region, by value, 2021 37
  • Figure 13 : North Americaosteoporosis drugs market share, by country, by value, 2021 40
  • Figure 14 : Number of hip fracture cases in European Union member states, 2000 – 2050 42
  • Figure 15 : Number of vertebra fracture cases in European Union member states, 2000 – 2050 42
  • Figure 16 : Europe osteoporosis drugs market share, by country, by value, 2021 43
  • Figure 17 : Asia Pacific osteoporosis drugs market share, by country, by value, 2021 46
  • Figure 18 : Drug focus analysis of osteoporosis drugs market 48
  • Figure 19 : Revenue and net income of Eli Lilly and Company, 2016–2020 (US$ Mn) 51
  • Figure 20 : Sales and net income of F. Hoffmann-La Roche, Ltd., 2016–2020 (US$Mn) 53
  • Figure 21 : Sales and net income of Merck & Co., Inc., 2016–2020 (US$Mn) 55
  • Figure 22 : Net sales and net income of Novartis AG, 2016–2020 (US$Mn) 57
  • Figure 23 : Total revenue and net income of Amgen, Inc., 2016–2020 (US$Mn) 59
  • Figure 24 : Novo Nordisk’s net sales and net profit, 2016 – 2020 (US$ Mn) 61
  • Figure 25 : Net revenue and net income of Actavis plc, 2016–2020 (US$ Mn) 63
  • Figure 26 : Revenue and net income of Pfizer, Inc., 2016–2020 (US$Mn) 66
  • Figure 27 : Turnover and total profit attributable to stakeholders of GlaxoSmithKline plc, 2016–2020 (US$Mn) 68
  • Figure 28 : Net revenue and net income of Teva Pharmaceutical Industries Ltd., 2016–2020 (US$Mn) 70

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organization of all sizes.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report